The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors by Eijck, C.H.J. (Casper) van et al.
ANNALS OF SURGERY
Vol. 224, No. 2, 119-124
© 1996 Lippincott-Raven Publishers
The Use of Somatostatin Receptor
Scintigraphy in the Differential
Diagnosis of Pancreatic Duct Cancers
and Islet Cell Tumors
Casper H. J. van Eijck, M.D., Ph.D.,* Steven W. J. Lamberts, M.D., Ph.D.,t
Luciene C. J. M. Lemaire, M.D.,* Hans Jeekel, M.D., Ph.D.,* Fre T. Bosman, M.D., Ph.D.,:
Jean-Claude Reubi, M.D.,Ph.D.,§ Hajo A. Bruining, M.D., Ph.D.,*
and Eric P. Krenning, M.D., Ph.D. 11
From the Departments of Surgery,* Intemal Medicine lI.t Pathology, and Nuclear Medicine, II
University Hospital, Rotterdam, The Netherlands; and the Department of Pathology,§ University
of Beme, Berne, Switzerland
Objective
In the present study, the diagnostic value of somatostatin receptor scintigraphy (SRS) was
evaluated in the preoperative workup in patients with pancreatic duct cancers and islet cell
tumors, as well as in the follow-up of these patients.
Methods
Twenty-six patients with suspected primary pancreatic duct cancers and 48 patients with islet cell
tumors were studied. The SRS was performed using the radionuclide-labeled somatostatin
analogue "'In-octreotide. Another group of 12 patients who were still alive more than 3 years after
pancreaticoduodenectomy for pancreatic duct adenocarcinomas also underwent SRS.
Results
In 31 (65%) of 48 patients, the primary pancreatic islet cell tumor as well as its often previously not
yet recognized metastases could be visualized. In contrast, none of the 26 pancreatic
adenocarcinomas or their metastases could be seen. In 5 of 12 patients who were alive more than
3 years after pancreaticoduodenectomy for pancreatic duct adenocarcinomas, metastatic lesions
were visualized at SRS. In retrospect, these patients were not operated on for adenocarcinomas
but for "nonfunctioning" islet cell tumors.
Conclusions
The present study supports the concept that SRS has a place in the preoperative differential
diagnosis of islet cell tumors and pancreatic duct cancers as well as in the follow-up, especially in
those cases in which no tumor histologic analysis was obtained, or the pathologic examination of
the tumor tissue had not included special staining procedures for neuroendocrine characteristics.
Our results also indicate that the evaluation of the results of investigations on the role of surgery or
radiation therapy and chemotherapy or both in pancreatic duct cancer have to be interpreted with
caution, if no histologic analysis and staining for neuroendocrine characteristics was performed.
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Somatostatin receptors (SS-Rs) have been found on
a variety of neuroendocrine tumors like carcinoids,
paragangliomas, as well as on brain tumors, such as
meningiomas.'3 The SS-Rs also are present on most
pancreatic islet cell tumors,4'5 whereas previous in vi-
tro studies indicate the absence of these receptors on
pancreatic duct cancers.6
Endocrine pancreatic tumors or islet cell tumors con-
stitute a small, but important, group of pancreatic tu-
mors. The annual incidence of islet cell tumors was
found to be 0.4 per 100.000 population.7 Most of these
tumors produce multiple hormones, but usually exces-
sive secretion of one hormone predominates, causing
specific clinical symptomatology.8'9 However, approxi-
mately 15% to 40% of islet cell tumors do not give rise
to hormone-related symptoms and are therefore called
"nonfunctioning."'O " The reasons why they are clini-
cally silent include the absence of the release hormones,
the production ofbiologically inactive prohormones, the
production ofhormones that do not cause clinical symp-
toms (e.g., pancreatic polypeptide, chromogranin A),
and downregulation of hormone receptors or the pro-
duction of inhibitory hormones, such as somatostatin,
or both.'2 Most patients with nonfunctioning islet cell
tumors have rather uncharacteristic symptoms at pre-
sentation. The correct diagnosis is therefore made at a
late stage when extensive tumor growth has oc-
curred.7"3"4 In general, islet cell tumors grow slowly, but
the significantly shorter survival of patients with non-
functioning islet cell tumors compared with those that
cause signs and symptoms of hormonal secretion indi-
cates a more malignant behavior of this subtype.7 How-
ever, this also might be because these tumors are diag-
nosed later. In 70% to 80% of the cases, liver metastases
are present at the time of diagnosis in patients with non-
functioning islet cell tumors.
Preoperative differentiation between pancreatic duct
carcinomas and islet cell tumors is of importance, be-
cause palliative surgery in patients with islet cell tumors
is not only of value to relieve clinical symptoms but also
to decrease the tumor burden, which might enhance the
effect of medical treatment. 15
Recently we introduced a new nuclear medical tech-
nique in which SS-R-positive tumors could be visualized
in vivo after the administration ofa radionuclide-labeled
somatostatin analogue followed by gamma-camera scin-
tigraphy.16-20 In the present study, we investigated the
diagnostic value of this technique in the workup of pa-
tients with pancreatic endocrine and exocrine tumors.
The results of this in vivo technique were correlated with
the results of in vitro receptor autoradiographic studies
in tumor specimen.
PATIENTS AND METHODS
Patients Selection
Twenty-six patients with primary pancreatic duct can-
cers (mean age, 64 years; range, 42-81) were studied. Af-
ter clinical and laboratory investigations searching for a
primary tumor in the pancreas, all patients underwent
ultrasonography, computed tomography (CT) scanning,
and endoscopic retrograde cholangiopancreatography.
Whenever possible, cytologic analysis of the tumor was
obtained. After informed consent was obtained from the
patient to participate in this study, somatostatin receptor
scintigraphy (SRS) was performed after bowel prepara-
tion on an outpatient basis. Without surgeons' taking
into consideration the scintigraphic results, 22 patients
were subsequently operated on for suspected pancreatic
duct carcinoma. Four patients were not operated on be-
cause of cytologically proven metastatic disease.
Tumor tissue specimens from these 22 patients who
were operated on were stained with hematoxylin and eo-
sin and examined for homogeneous cell structure and
characteristic growth patterns ofexocrine and endocrine
tumors. The Grimelius silver staining technique was
used, as well as immunocytochemical staining with anti-
sera against neuron-specific enolase and chromogranin
A to confirm a possible endocrine nature of the tumor.
In addition, immunocytochemical staining with antisera
against insulin, gastrin, pancreatic polypeptide, vaso-
active intestinal polypeptide, somatostatin, glucagon,
and neurotensin was performed. Tumors were histologi-
cally classified by one pathologist, who was not informed
about the SRS results. Whenever enough tumor tissue
was available, the presence of SS-Rs was studied by in
vitro autoradiographic analysis on cryostat sections, as
has been described previously.4
Another group of 12 patients who were still alive more
than 3 years after subtotal (n = 10) or total (n = 2) pancre-
aticoduodenectomy performed for pancreatic duct adeno-
carcinomas also underwent an SRS. Five of these patients
were known to have metastatic disease when SRS was per-
formed. Revision ofthe tumor blocks ofthese patients that
had been previously reviewed by other pathologists took
place as described above. No more autoradiographic anal-
ysis could be done on these tumor specimens.
The results of the scintigraphy of the patients described
above where compared with the results obtained in 48 pa-
tients with endocrine pancreatic tumors. Part ofthe results
obtained in 25 individuals have been described pre-
viously.2'
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Figure 1. Top left. Twenty-four hour transversal single photon emis-
sion computed tomography abdominal [1'1In-DTPA-D-Phe']-octreotide
scintigram of a patient with a "nonfunctioning" islet cell tumor showing
a hot spot at the side of the primary tumor in the caput of the pancreas
(arrow) between the kidneys. Top right. Many hot spots (yellow) in
the liver representing metastases (spleen in white). These metastases
could not be visualized by ultrasound or computed tomography scan.
Figure 2. Left. ['I11n-DTPA-D-Phe']-octreotide scan of a 1.5-cm insu-
linoma in the head of the pancreas (arrow). Anterior view of the abdo-
men obtained at 24 hours.
Material
The somatostatin analogue [DTPA-D-Phe']-octreo-
tide (Mallinckrodt Medical BV, Petten, The Nether-
lands) was labeled with "ultra-pure" Indium 11 1 ([ "'In],
Mallinckrodt Medical BV, Petten, The Netherlands).
The labeling procedure has been described elsewhere.22
Doses ranged from 222 MBq to 272 MBq ["'In-DTPA-
D-Phel]-octreotide.
Scintigraphy
After bowel preparation (2 L polyethyleneglycol), pla-
nar and, in most patients, also single photon emission
computed tomography images were obtained as de-
scribed previously.20'23
RESULTS
["'In-DTPA-Phel]-octreotide scintigraphy (SRS) was
carried out before operation in 26 patients with sus-
pected pancreatic duct carcinomas. None of these tu-
mors or their metastases could be visualized. Twelve pa-
tients were subsequently treated by a Whipple proce-
dure, 2 by total pancreatectomy, 2 patients by a palliative
procedure (gastroenterostomy or choledochoduodenos-
tomy or both) after transduodenal biopsy was per-
formed, and 6 patients had a biopsy only. Four patients
were not operated on because cytologic analysis of sus-
pected lesions in the liver showed adenocarcinoma. Pan-
creatic duct carcinoma was found in 18 patients who
were operated on. None of these tumors showed neuro-
endocrine characteristics. In 16 of these tumors, autora-
diographic studies ofthe surgically removed tumor tissue
could be done and no SS-Rs were present. In two pa-
tients, the tumor was so extensive that no resection could
be done. Transduodenal biopsies in these two patients,
however, showed atypia without any evidence of infil-
trating tumor cells, which must be considered a sampling
error. The other two patients underwent a Whipple pro-
cedure for chronic pancreatitis. In these patients also, no
abnormalities were detected at SRS. No autoradio-
graphic analysis was done on the tissue ofthese patients.
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Table 1. INCIDENCE OF SOMATOSTATIN
RECEPTORS ON ENDOCRINE PANCREATIC
TUMORS IN VWVO AND IN VITRO AS
DEMONSTRATED BY SCINTIGRAPHY AND
AUTORADIOGRAPHY
In Vivo In Vitro
Vipomas 1/1 1/1
Gastrinomas 13/14 10/11
Glucagonomas 1/1 1/1
Insulinomas 13/28 8/11
"Nonfunctioning" islet cell tumors 2/2 2/2
Somatostinomas 1/2 -
Because long-term survival ofpatients with pancreatic
duct carcinoma is rare, we looked in retrospect at our
group oflong-term survivors after surgery for pancreatic
duct carcinomas. Long-term survivors were defined as
patients who lived more than 3 years after the primary
operation. Of62 patients who had been operated on be-
tween 1985 and 1990, 12 patients were found to be alive
for 3 or more years. Five ofthese 12 patients were known
to have metastases. These 12 patients underwent SRS. In
seven patients, no abnormalities were seen, whereas
other investigations also suggested that these patients
were tumor free at that moment. However, in five "sur-
vivors" in whom the presence of metastases was known,
all metastatic lesions as well as a number of additional
tumor sites were visualized at SRS. Examples ofthe scin-
tigram obtained in one of these patients are shown in
Figure 1.
Revision of the original tumor blocks, including the
additional staining procedures mentioned above,
showed that these five patients in retrospect were oper-
ated on primarily for nonfunctioning islet cell tumors. In
the group of seven patients without known metastases
and without abnormalities at SRS, revision ofthe patho-
logic analysis confirmed that these patients indeed had
been cured from pancreatic duct cancer.
Table 1 lists the results of in vivo scintigraphy of a
group of 48 patients with different islet cell tumors.
Twenty-one of the tumors have been investigated both
in vitro and in vivo. In all cases, the results in vitro and in
vivo investigations were parallel.
The application ofSS-R imaging proved to be highly suc-
cessful. The primary endocrine pancreatic tumors as well
as their often previously not yet recognized metastases
could be visualized in 31 (65%) ofthese 48 patients. Metas-
tases were actually scintigraphically evident in 13 patients.
Twenty-six ofthese patients subsequently were operated on
in our hospital, allowing surgical evaluation of the scinti-
graphic results. In one patient with gastrinoma, no lymph
node metastasis on the aortic arch was found at operation,
despite it being suggested at CT scanning. In another pa-
tient with gastrinoma who had familial multiple endocrine
adenomatosis type I, the scintigraphically detected tumor
was indeed found in the tail of the pancreas, but during
operation, an additional islet cell tumor was found in the
corpus of the pancreas. This tumor had not been seen on
SRS. Unfortunately, no somatostatin autoradiographic
analysis ofthis tumor was done.
The visualization of insulinomas with this technique
proved to be more difficult. We localized the tumors with
SRS in only 13 of28 patients investigated to date. In vitro
autoradiographic analysis showed that all insulinomas
contained receptors for somatostatin- 14 and somato-
statin-28, but that octreotide receptors were absent on
the tumors, which could not be visualized in vivo. An
example of the gamma picture obtained in one patient
with an insulinoma is shown in Figure 2.
DISCUSSION
After Schonbrunn and Tashjian first measured SS-Rs
in 1978 using the clonal pituitary cell line GH4C,24 SS-
Rs have been shown on a variety ofhuman tumors, using
various iodinated SS analogues in homogenate ligand-
binding assays or autoradiographic analysis on tissue sec-
tions.25'26 Large numbers of binding sites with high
affinity for SS were found on most tumors with amine
precursor uptake and decarboxylation (APUD) charac-
teristics, as well as on meningiomas, well-differentiated
brain tumors (astrocytomas), neuroblastomas, and hu-
man breast tumors.27 Examples oftumors with amine
precursor uptake and decarboxylation characteristics
that are often SS-R-positive are growth-hormone-pro-
ducing pituitary adenomas, endocrine pancreatic tu-
mors, carcinoids, paragangliomas, small cell lung can-
cers, medullary thyroid carcinomas, and pheochromo-
cytomas. Recently, at least five different human SS-R
subtypes have been cloned.""8 Octreotide binds with
high affinity to subtype 2 (SSTR2), whereas this analogue
has a relatively low affinity to SSTR3 and SSTR5 and
shows no binding to subtypes 1 and 4 (SSTR1 and,
SSTR4). The majority ofthe receptor-positive human tu-
mors expressed the SS-R2 subtype, whereas only a mi-
nority oftumors had exclusively other SS-R subtypes.47
For the visualization ofSS-R-positive tumors, we used
a radionuclide-labeled somatostatin analogue, ["'In-
DTPA-D-Phe']-octreotide, because there are several ar-
guments that octreotide scintigraphy represents SS-R
imaging. Pretreatment with high doses of unlabeled oc-
treotide prevents tumor uptake of ["'In-DTPA-D-
Phe']-octreotide in rats bearing SS-R-positive tumors.22
Autoradiographically, it also was found that only the an-
terior lobe of the rat pituitary, which is the only part of
this organ with SS-Rs, showed specific binding ofthe ra-
dioligand after its injection.49 As has been found in our
study as well, a close relation exists between the presence
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ofSS-Rs, showed with in vitro autoradiographic analysis,
and the visualization of tumors and diseases by in vivo
octreotide scintigraphy.
There are many promising reports on the potential ben-
efit of radiolabeled monoclonal antibodies for in vivo tu-
mor detection. However, their widespread application has
been hampered for several reasons. The low tumor-to-
background ratios achieved with this technique is because
ofthe large molecules often used, which lead to a high back-
ground radioactivity. Because ofthe rapid clearance ofthe
small-sized [I ' In-DTPA-D-Phe']-octreotide by the kid-
neys, a much higher tumor-to-background ratio can be ob-
tained. Antibody formation, which often can be found after
administration ofmonoclonal antibodies, is extremely rare
in patients treated with octreotide. Therefore, the SS-R im-
aging can be repeated easily without any risk ofan anaphy-
lactic reaction.
Generally, patients with pancreatic islet cell tumors have
a better prognosis than those with exocrine, mostly ductal
adenocarcinomas.50 However, despite improvements in di-
agnostic methods, the median delay between the appear-
ance of the first symptoms and the diagnosis has not been
reduced, and most patients are encountered when the tu-
mor has reached an advanced stage.8"3",4 As pointed out by
Eriksson et al.,7 there is a need for optimalization ofscreen-
ing patients with uncharacteristic abdominal symptoms for
the presence of islet cell tumors. In addition to the mea-
surements ofplasma levels ofchromogranin A and pancre-
atic hormones, SS-R scintigraphy can be used to show the
presence ofsuch tumors.
In this study, the sensitivity of the SS-R scintigraphy
in localizing islet cell tumors was high, except in the case
of insulinomas. The presence of other subtypes ofSS-Rs
in this tumor is well known. Only approximately 60%
of the insulinomas express the SSTR2 subtype, and this
necessitates the development of other radionuclide-la-
beled somatostatin analogues that recognize other sub-
types of the SS-R. Other factors that generally may in-
terfere with the visualization of neuroendocrine tumors
include the presence of unlabeled somatostatin (e.g., by
autocrine, paracrine, or endocrine production of so-
matostatin or somatostatin analogue administration). In
both cases, this may result in receptor blockade or
"down" regulation ofthe receptor.
Finally, the difference in SS-R expression between islet
cell tumors and pancreatic duct cancers seems to offer
the possibility to differentiate between these tumors be-
fore operation. This is important, because palliative sur-
gery in patients with islet cell tumors is not only ofvalue
to relieve clinical symptoms but also to decrease tumor
burden, which might enhance the effect of medical treat-
ment, resulting in a better clinical condition and a longer
survival.'5 The use of SS-R scintigraphy as a diagnostic
technique for suspected islet cell tumors is favored be-
cause of its harmless, noninvasive nature. In islet cell tu-
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mors, ultrasound and CT are usually limited to the
pancreas and liver region, thereby missing possible
extra-abdominal metastases. Further studies compar-
ing intraoperative ultrasound, surgical palpation, and
guided surgery using a hand-held radionuclide-detect-
ing probe after the administration of [ "'In-DTPA-D-
Phe']-octreotide are necessary to determine the best
method to localize the endocrine tumor before opera-
tion. Therefore, the SS-R scintigraphy should be per-
formed to see if the tumor contains SS-Rs, to support
diagnosis ofan islet cell tumor, and to stage the patient
directly.
The present study supports the concept that SRS may
have a place in the preoperative differential diagnosis of
endocrine pancreatic tumors, especially nonfunctioning
islet cell tumors, and pancreatic ductal cancers, as well
as in the follow-up, especially in those cases in which the
pathologic examination of the tumor tissue had not in-
cluded special staining procedures for neuroendocrine
characteristics. Our results also indicate that the evalua-
tion of the investigative results on the role of surgery or
radiation therapy and chemotherapy or both in pancre-
atic duct cancer have to be interpreted with caution, if
no histologic analysis and staining for neuroendocrine
characteristics were performed.
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